CPT code 0064U is a Proprietary Laboratory Analyses (PLA) CPT code for the BioPlex™ 2200 Syphilis Total & RPR Assay, a single immunoassay panel that measures total treponemal antibody and non-treponemal rapid plasma reagin (RPR) antibody to support syphilis diagnosis and treatment management. PLA codes like 0064U identify manufacturer‑ or lab‑specific tests and matter nationally because they affect laboratory billing transparency, payer coverage decisions, and the integration of novel diagnostics into clinical pathways.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a compact review of what 0064U represents clinically, the typical site of service, and which payers commonly evaluate coverage for PLA laboratory tests. The publication outlines benchmarks and policy-relevant considerations such as PLA code implications for claims processing, how payers may apply coverage criteria for proprietary syphilis assays, and typical billing contexts in which 0064U appears. Clinical context on the assay’s dual treponemal and non‑treponemal targets is included to clarify when the test is used in diagnosis and treatment monitoring.

Data not available in the input includes specific payer coverage policies, reimbursement rates, detailed denial patterns, associated taxonomies, and ICD-10 diagnosis pairings.